Jack Higgins Sells 13,200 Shares of Immunome (NASDAQ:IMNM) Stock

Key Points

• Immunome insider Jack Higgins sold 13,200 shares at an average price of $25.32, generating $334,224. The transaction was made under a pre-arranged Rule 10b5-1 plan, leaving him with 65,050 shares.
• Immunome shares fell 2.4% to $23.95, while the company’s latest quarterly loss of $0.65 per share missed analyst expectations of a $0.51 loss.
• Analyst sentiment remains broadly positive, with 12 Buy ratings and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $34.64.

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) insider Jack Higgins sold 13,200 shares of the company's stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the sale, the insider directly owned 65,050 shares of the company's stock, valued at approximately $1,647,066. This represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Stock Down 2.4%

IMNM traded down $0.60 during trading on Tuesday, hitting $23.95. The company's stock had a trading volume of 1,165,720 shares, compared to its average volume of 1,334,804. The business's 50 day simple moving average is $25.34 and its 200-day simple moving average is $22.73. The firm has a market cap of $2.72 billion, a PE ratio of -9.47 and a beta of 2.13. Immunome, Inc. has a one year low of $8.93 and a one year high of $30.06.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.14). Equities research analysts expect that Immunome, Inc. will post -2.38 EPS for the current fiscal year.

Institutional Trading of Immunome

Institutional investors have recently made changes to their positions in the business. Allworth Financial LP bought a new position in Immunome during the second quarter valued at approximately $25,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Immunome during the 2nd quarter worth approximately $27,000. KBC Group NV bought a new position in shares of Immunome during the 1st quarter valued at approximately $60,000. Assetmark Inc. grew its holdings in shares of Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company's stock valued at $99,000 after purchasing an additional 1,442 shares in the last quarter. Finally, State of Wyoming purchased a new position in shares of Immunome in the second quarter valued at $109,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

Analyst Upgrades and Downgrades

IMNM has been the topic of a number of analyst reports. Barclays initiated coverage on Immunome in a research report on Thursday, May 28th. They set an "overweight" rating and a $36.00 price objective on the stock. Truist Financial increased their target price on shares of Immunome from $37.00 to $38.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Wall Street Zen cut shares of Immunome from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Wedbush lifted their price target on shares of Immunome from $31.00 to $35.00 and gave the company an "outperform" rating in a report on Wednesday, August 12th. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Immunome in a research report on Thursday, September 10th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Immunome presently has an average rating of "Moderate Buy" and a consensus price target of $34.64.

Immunome Company Profile

Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development.

Immunome's activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.